Sensitivity analyses and publication bias. We provide the results of the two sensitivity analyses: by excluding studies with high risk of bias (Table S20) and by including the results of Nakamura et al. 2014 pooled analysis (Table S21); and the funnel plots of study outcomes (Figure S10). (DOCX 291 kb
Taro Kishi,1,* Shinji Matsunaga,1,2,* Nakao Iwata1 1Department of Psychiatry, Fujita Health Univers...
Background: Postmarketing surveillance studies (PMS) are an important tool for evaluating a drug's e...
Background: Alzheimer's disease ( AD) is a progressive neurodegenerative disorder and delaying disea...
Risk of bias of included clinical trials. We provide the risk of bias of included studies on differe...
Characteristics of included clinical trials. We provide the references of included studies (Table S1...
PRISMA checklist and search strategies. We provide the PRISMA checklist (Table S1) and search strate...
Supplementary 1. Network meta-analysis model. Supplementary 2. References for included trials. Suppl...
The risk-benefit relationship of memantine treatment for Alzheimer’s disease (AD) remains unclear. I...
To study the impact of donepezil, rivastigmine, galantamine, and memantine on cognitive, functional,...
Shows the authorsâ judgements for risk of bias assessment domains with supporting reasons. (DOCX 2...
To study the impact of donepezil, rivastigmine, galantamine, and memantine on cognitive, functional,...
Background We performed an updated meta-analysis of randomized placebo-controlled trials testing mem...
After careful review of the article entitled ‘Systematic review and meta-analysis of combi-nation th...
Background/Aims: In this post-marketing observational study, the safety and effectiveness of memanti...
The Author(s) 2013. This article is published with open access at Springerlink.com Introduction Imme...
Taro Kishi,1,* Shinji Matsunaga,1,2,* Nakao Iwata1 1Department of Psychiatry, Fujita Health Univers...
Background: Postmarketing surveillance studies (PMS) are an important tool for evaluating a drug's e...
Background: Alzheimer's disease ( AD) is a progressive neurodegenerative disorder and delaying disea...
Risk of bias of included clinical trials. We provide the risk of bias of included studies on differe...
Characteristics of included clinical trials. We provide the references of included studies (Table S1...
PRISMA checklist and search strategies. We provide the PRISMA checklist (Table S1) and search strate...
Supplementary 1. Network meta-analysis model. Supplementary 2. References for included trials. Suppl...
The risk-benefit relationship of memantine treatment for Alzheimer’s disease (AD) remains unclear. I...
To study the impact of donepezil, rivastigmine, galantamine, and memantine on cognitive, functional,...
Shows the authorsâ judgements for risk of bias assessment domains with supporting reasons. (DOCX 2...
To study the impact of donepezil, rivastigmine, galantamine, and memantine on cognitive, functional,...
Background We performed an updated meta-analysis of randomized placebo-controlled trials testing mem...
After careful review of the article entitled ‘Systematic review and meta-analysis of combi-nation th...
Background/Aims: In this post-marketing observational study, the safety and effectiveness of memanti...
The Author(s) 2013. This article is published with open access at Springerlink.com Introduction Imme...
Taro Kishi,1,* Shinji Matsunaga,1,2,* Nakao Iwata1 1Department of Psychiatry, Fujita Health Univers...
Background: Postmarketing surveillance studies (PMS) are an important tool for evaluating a drug's e...
Background: Alzheimer's disease ( AD) is a progressive neurodegenerative disorder and delaying disea...